文献速递造血干细胞移植与细胞治疗

猪抗人T细胞免疫球蛋白联合益赛普治疗35例Ⅲ/Ⅳ度急性GVHD

[Clinical study of anti-human T cell porcine immunoglobulin with recombinant human tumor necrosis factor-α receptor II: IgG Fc in the treatment of 35 cases of grade III/IV acute graft-versus-host disease after allo-HSCT].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2020-01-01

该回顾性研究分析了35例异基因造血干细胞移植后Ⅲ/Ⅳ度急性GVHD患者,接受P-ATG联合益赛普治疗。28天总有效率85.7%,Ⅲ度组优于Ⅳ度组;56天总有效率77.2%。主要并发症为感染,CMV再激活率77.1%,1年总生存率68.1%。

要点

  • P-ATG联合益赛普治疗Ⅲ/Ⅳ度aGVHD的28天总有效率为85.7%。
  • Ⅲ度aGVHD组28天和56天总有效率均显著高于Ⅳ度组。
  • 主要治疗相关并发症为感染,CMV再激活率77.1%。

核心结论

  • P-ATG联合益赛普治疗allo-HSCT后Ⅲ/Ⅳ度aGVHD有较好的疗效和安全性。

研究设计与样本

  • 回顾性分析35例allo-HSCT后合并Ⅲ/Ⅳ度aGVHD患者,接受P-ATG联合益赛普治疗。

主要发现

  • 28天总有效率85.7%(30/35),完全缓解率34.3%(12/35),部分缓解率51.4%(18/35)。
  • 56天总有效率77.2%(27/35),完全缓解率62.9%(22/35),部分缓解率14.3%(5/35)。
  • Ⅲ度aGVHD组28天总有效率100%(19/19)高于Ⅳ度组68.8%(11/16),P=0.004。
  • Ⅲ度aGVHD组56天总有效率89.5%(17/19)高于Ⅳ度组62.5%(10/16),P=0.009。
  • 中位随访13(1-55)个月,1年和2年总生存率分别为(68.1±8.0)%和(64.3±8.4)%。

关键数值与推荐

  • P-ATG剂量为5 mg·kg(-1)·d(-1)用3至5天,序贯5 mg/kg隔日1次至每周2次。
  • 益赛普剂量为25 mg每周2次,儿童为12.5 mg每周2次。
  • CMV和EBV再激活率分别为77.1%(27/35)和22.9%(8/35),细菌感染率48.6%(17/35)。
  • Ⅲ度aGVHD组1年总生存率(84.2±8.4)%高于Ⅳ度组(47.6±13.1)%,P=0.05。

临床怎么用

  • 对于allo-HSCT后Ⅲ/Ⅳ度aGVHD患者,可考虑P-ATG联合益赛普方案。
  • 治疗中需密切监测CMV、EBV再激活及细菌感染。

局限性

  • 本研究为单中心回顾性分析,样本量35例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the efficacy and safety of anti-human T lymphocyte porcine immunoglobulin (P-ATG) with recombinant human tumor necrosis factor-α receptor Ⅱ:IgG Fc fusion protein (rhTNFR∶Fc, Etanercept) on grade Ⅲ/Ⅳ acute graft-versus-host disease (aGVHD) after allogenic hematopoietic stem cell transplantation (allo-HSCT) . Methods: Thirty-five patients with Grade Ⅲ/Ⅳ aGVHD who received P-ATG with etanercept therapy after allo-HSCT were retrospectively analyzed. P-ATGs (5 mg·kg(-1)·d(-1)) were administrated for 3 to 5 days, and then 5mg/kg was sequentially administrated, QOD to BIW. Etanercepts were administrated 25 mg, twice a week (12.5 mg, BIW for pediatric patients) . Results: Among the 35 patients with grade Ⅲ/Ⅳ aGVHD, 21 were males and 14 females, with a median age of 10 (3-54) years. A total of 19 cases of acute myeloid leukemia, 13 of acute lymphoblastic leukemia, 1 of severe aplastic anemia, 1 of myelodysplastic syndrome, and 1 of mixed phenotypic acute leukemia were noted. The overall response (OR) rate of P-ATG with etanercept was 85.7% (30/35) , with complete response (CR) and partial response (PR) rates of 34.3% (12/35) and 51.4% (18/35) , respectively, on day 28. The OR rate of grade Ⅲ aGVHD group was higher than of grade IV aGVHD group [100% (19/19) vs. 68.8% (11/16) , P=0.004]. On day 56, the OR rate became 77.2% (27/35) , with CR and PR rates of 62.9% (22/35) and 14.3% (5/35) , respectively. The OR rate of grade Ⅲ aGVHD group was also higher than of grade Ⅳ aGVHD group [89.5% (17/19) vs. 62.5% (10/16) , P=0.009]. Thirty-five patients had no adverse effects such as fever, chills, and rash during the P-ATG infusion, and no obvious liver and kidney function damage was observed after treatment. The main treatment-related complication was infection. The reactivation rates of CMV and EBV were 77.1% (27/35) and 22.9% (8/35) , respectively, and the bacterial infection rate was 48.6% (17/35) . With a median follow-up time of 13 (1-55) months after HSCT, the 1-year and 2-year OS rates were (68.1±8.0) % and (64.3±8.4) % , respectively. The 1-year OS rate of grade Ⅲ aGVHD group was superior to grade Ⅳ aGVHD group [ (84.2±8.4) % vs. (47.6±13.1) % , χ(2)=3.38, P=0.05]. Conclusion: This study demonstrated that P-ATG with etanercept was effective and safe in treating grade Ⅲ-Ⅳ aGVHD after allo-HSCT. 目的: 评估抗人T细胞猪免疫球蛋白(P-ATG)联合重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白(益赛普)治疗Ⅲ/Ⅳ度急性移植物抗宿主病(aGVHD)的疗效及安全性。 方法: 对接受P-ATG(5 mg·kg(-1)·d(-1)×3~5 d,序贯5 mg/kg隔日1次~每周2次)联合益赛普(25 mg每周2次,儿童剂量减半)方案治疗的35例异基因造血干细胞移植(allo-HSCT)后合并Ⅲ/Ⅳ度aGVHD患者进行回顾性分析。 结果: ①35例Ⅲ/Ⅳ度aGVHD患者中,男21例,女14例,中位年龄10(3~54)岁。急性髓系白血病(AML)19例,急性淋巴细胞白血病(ALL)13例,重型再生障碍性贫血(SAA)、骨髓增生异常综合征(MDS)、混合表型急性白血病(MPAL)各1例。②治疗28 d疗效评估:完全缓解(CR)12例(34.3%),部分缓解(PR)18例(51.4%),总有效率为85.7%(30/35),Ⅲ度aGVHD组总有效率高于Ⅳ度aGVHD组[100%(19/19)对68.8%(11/16),P=0.004]。③治疗56 d疗效评估:CR 22例(62.9%),PR 5例(14.3%),总有效率为77.2%(27/35),Ⅲ度aGVHD组总有效率高于Ⅳ度aGVHD组[89.5%(17/19)对62.5%(10/16),P=0.009]。④不良反应:35例患者输注P-ATG过程中均为发生发热、寒战、皮疹等不良反应,亦无明显肝肾功能损害发生。巨细胞病毒、EB病毒再激活率分别为77.1%(27/35)、22.9%(8/35),细菌感染发生率为48.6%(17/35)。⑤中位随访时间为13(1~55)个月,移植后1、2年的总生存率分别为(68.1±8.0)%、(64.3±8.4)%,Ⅲ度aGVHD组移植后1年总生存率高于Ⅳ度aGVHD组[(84.2±8.4)%对(47.6±13.1)%,χ(2)=3.38,P=0.05]。 结论: P-ATG联合重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗allo-HSCT后Ⅲ/Ⅳ度aGVHD有较好的疗效和安全性。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Liu DY, Yan S, Ma DD, et al. [Clinical study of anti-human T cell porcine immunoglobulin with recombinant human tumor necrosis factor-α receptor II: IgG Fc in the treatment of 35 cases of grade III/IV acute graft-versus-host disease after allo-HSCT]. Zhonghua Xue Ye Xue Za Zhi. 2020. PMID: 33113606. doi:10.3760/cma.j.issn.0253-2727.2020.09.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。